Related scientific articles (all)

Loss of ARID1A activates ANXA1, which serves as a predictive biomarker for trastuzumab resistance.

Authors : Berns K, Sonnenblick A, Gennissen A, Brohée S, Hijmans ME, Evers B, Fumagalli D, Desmedt C, Loibl S, Denkert C, Neven P, Guo W, Zhang F, Knijnenburg TA, Bosse T, van der Heijden MS, Hindriksen S, Nijkamp W, Wessels LF, Joensuu H, Mills GB, Beijersbergen RL, Sotiriou C, Bernards R
Year : 2016
Journal : Clin Cancer Res
Volume : 22(21)
Pages : 5238-48

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Authors : Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart-Gebhart M, Von Minckwitz G, Baselga J
Year : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1519-25

Consensus on precision medicine for metastatic cancers: a report from the MAP conference.

Authors : Swanton C, Soria JC, Bardelli A, Biankin A, Caldas C, Chandarlapaty S, de Koning L, Dive C, Feunteun J, Leung SY, Marais R, Mardis ER, McGranahan N, Middleton G, Quezada SA, Rodón J, Rosenfeld N, Sotiriou C, André F
Year : 2016
Journal : Ann Oncol
Volume : 27(8)
Pages : 1443-8

Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.

Authors : Azim HA Jr, Davidson NE, Ruddy KJ
Year : 2016
Journal : Am Soc Clin Oncol Educ Book
Volume : 35
Pages : 23-32

Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.

Authors : Sonnenblick A, de Azambuja E, Agbor-Tarh D, Bradbury I, Campbell C, Huang Y, Dueck AC, Pritchard KI, Wolff AC, Jackisch C, Lang I, Untch M, Smith I, Boyle F, Xu B, Gomez H, Perez EA, Piccart-Gebhart M, Azim HA Jr
Year : 2016
Journal : J Natl Cancer Inst
Volume : 108

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Authors : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Year : 2016
Journal : Gut
Volume : 65(6)
Pages : 990-1000

The topography of mutational processes in breast cancer genomes.

Authors : Morganella S, Alexandrov LB, Glodzik D, Zou X, Davies H, Staaf J, Sieuwerts AM, Brinkman AB, Martin S, Ramakrishna M, Butler A, Kim HY, Borg Å, Sotiriou C, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Stunnenberg HG, Van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Sale J, Rada C, Stratton MR, Birney E, Nik-Zainal S
Year : 2016
Journal : Nat Commun
Volume : 7
Pages : 11383

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Authors : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Year : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pages : 1040-7

Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Authors : Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GK, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, OMeara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Veer LV, Tutt A, Knappskog S, Tan BK, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, Van de Vijver MJ, Martens JW, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR
Year : 2016
Journal : Nature
Volume : 534(7605)
Pages : 47-54

Adjuvant chemotherapy in elderly patients with breast cancer: key challenges.

Authors : Pondé N, Dal Lago L, Azim HA Jr
Year : 2016
Journal : Expert Rev Anticancer Ther
Volume : 16(6)
Pages : 661-71

Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers.

Authors : Denkert C, Von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, Pfitzner BM, Salat C, Loi S, Schmitt WD, Schem C, Fisch K, Darb-Esfahani S, Mehta K, Sotiriou C, Wienert S, Klare P, André F, Klauschen F, Blohmer J, Krappmann K, Schmidt M, Tesch H, Kümmel S, Sinn P, Jackisch C, Dietel M, Reimer T, Untch M, Loibl S
Year : 2015
Journal : J. Clin. Oncol.
Volume : 33(9)
Pages : 983-91

Harmonization of the evaluation of tumor infiltrating lymphocytes (TILs) in breast cancer: recommendations by an international TILs-working group 2014.

Authors : Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, Wienert S, Van den Eynden G, Baehne FL, Penault-Llorca F, Perez EA, Thompson EA, Symmans WF, Richardson AL, Brock J, Criscitiello C, Bailey H, Ignatiadis M, Floris G, Sparano J, Kos Z, Nielsen T, Rimm DL, Allison KH, Reis-Filho JS, Loibl S, Sotiriou C, Viale G, Badve S, Adams S, Willard-Gallo K, Loi S
Year : 2015
Journal : Ann Oncol
Volume : 26(2)
Pages : 259-71

CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer-Where Did It Start and Where Are We Now?

Authors : Gingras I, Desmedt C, Ignatiadis M, Sotiriou C
Year : 2015
Journal : Clin Cancer Res
Volume : 21
Pages : 4743-6

Genomic aberrations in young and elderly  breast cancer patients.

Authors : Azim HA, Nguyen B, Brohée S, Zoppoli G, Sotiriou C
Year : 2015
Journal : BMC Med
Volume : 13
Pages : 266

Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial.

Authors : Sonnenblick A, Brohée S, Fumagalli D, Rothé F, Vincent D, Ignatiadis M, Desmedt C, Salgado R, Sirtaine N, Loi S, Neven P, Loibl S, Denkert C, Joensuu H, Piccart-Gebhart M, Sotiriou C
Year : 2015
Journal : Oncotarget
Volume : 6
Pages : 30306-16

Evolving paradigms in multifocal breast cancer.

Authors : Salgado R, Aftimos P, Sotiriou C, Desmedt C
Year : 2015
Journal : Semin. Cancer Biol.
Volume : 31C
Pages : 111-118

Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome.

Authors : Fumagalli D, Gacquer D, Rothé F, Lefort A, Libert F, Brown D, Kheddoumi N, Shlien A, Konopka T, Salgado R, Larsimont D, Polyak K, Willard-Gallo K, Desmedt C, Piccart-Gebhart M, Abramowicz M, Campbell PJ, Sotiriou C, Detours V
Year : 2015
Journal : Cell Rep
Volume : 13
Pages : 277-89

Immunology and breast cancer: toward a new way of understanding breast cancer and developing novel therapeutic strategies.

Authors : Gingras I, Azim HA Jr, Ignatiadis M, Sotiriou C
Year : 2015
Journal : Clin Adv Hematol Oncol
Volume : 13
Pages : 372-82

St Gallen International Expert Consensus on the primary therapy of early breast cancer: an invaluable tool for physicians and scientists.

Authors : Ignatiadis M, Buyse M, Sotiriou C
Year : 2015
Journal : Ann Oncol
Volume : 26(8)
Pages : 1519-20

Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity.

Authors : Van Keymeulen A, Lee MY, Ousset M, Brohée S, Rorive S, Giraddi RR, Wuidart A, Bouvencourt G, Dubois C, Salmon I, Sotiriou C, Phillips WA, Blanpain C
Year : 2015
Journal : Nature
Volume : 525(7567
Pages : 119-23